Home » Our Labs » Chongqing Lab

CHINA

Chongqing Lab

Founded in 2017

Our laboratory in Chongqing, China, established in 2017, provides GxP bioanalytical services. Its core leadership has extensive working experience in the US and China CRO industry.

Modern laboratory with multiple workstations. Chongqing, China, Resolian Bioanalytics

Lab Description

The site employs 70 scientists operating from 3,500 square meters of purpose-built, state-of-the-art analytical labs.

It is equipped with the world’s most advanced instruments, while its quality assurance system is established in strict accordance with domestic and foreign laws and regulations related to bioanalysis.

The site is the industry leader in China in the bioanalysis of oligonucleotide drugs and mRNA vaccines (PK/PD and ADA), liposomal drug (free and encapsulated drug), ultra-sensitive assays for inhalation drugs, and biomarker assays.

Resolian Bioanalytics Chongqing
Building B9, Dadi Enterprise Park, No. 88 Fenghe Road, Beibei District, Chongqing

changing

Unique Site-specific Expertise

  • Large molecule (LBA & LC-MS) bioanalysis (including oligonucleotides)
  • Ultra-high sensitivity methods
  • qPCR (including mRNA vaccines and BSL-2 [China level])
  • Liposomal drugs (free drug, encapsulated drug and total drug concentrations)
  • Micellar drugs (free drug and total drug concentrations)
  • Lipid drug carriers (PEG20000, PEI25000, PEG2000-DMG, 
Dlin-MC3, ALC-0315 and ALC-0159 etc.)
  • Vitamin D and K analogdrugs (Calcitriol, Alfacalcidol, Eldecalcitol, Paracalcitol, Vitamin K1, Vitamin K2, etc.)
  • Inhalation drugs (Fluticasone, Salmeterol, Indacaterol, Budesonide, Tiotropium, Formoterol, etc.)
  • Ocular drugs

Technology / Platform / Instruments

UHPLC

LC-MS

Immunoassay

Cell & Gene Therapy

Automation

UHPLC

  • Shimadzu Nexera X2

  • Shimadzu LC-30A

  • Shimadzu RF-20Axs FLD

  • Shimadzu SPD-20A UV/VIS

  • Evosep One EV-1000

LC-MS

  • Sciex 5500 – 6500+

  • Sciex 7500

  • Thermo QE HRMS

  • Agilent 7700 ICP-MS

  • Thermo Q Exactive Plus

Immunoassay

  • MESO QuickPlex SQ 120

  • BioTek Synergy H1Hybrid Multi-Mode Reader

  • Biotek Plate Washers

  • MD SpectraMax M3 
    Multi-Mode Reader

  • ProteinSimple Ella Simple Plex ELISA system

  • NanoDrop One Spectrophotometer

Cell & Gene Therapy

  • BioRad CFX Connect™ qPCR

  • BioRad T100™
    Thermo Cycler

  • BioRad ChemiDoc
    XRS+ Imager

  • Amersham ImageQuant 800 Imager

Automation

  • Tomtec Quadra 4

  • Auto-Pure-96 Nucleic Acid Extraction System

  • 350 m² BSL2+ Biosafety and Cell Culture Laboratory

  • Thermo Watson LIMS

Chongqing, China FAQs

When was the Chongqing lab established and how big is it?

The Chongqing lab was established in 2017 and operates from 3,500 square metres of purpose-built space, staffed by 70 scientists.

What is the Chongqing lab known for within China's bioanalytical market?

The site is recognised as an industry leader in China for bioanalysis of oligonucleotide drugs and mRNA vaccines, covering both PK/PD and anti-drug antibody (ADA) work, plus liposomal drug analysis and ultra-sensitive assays for inhalation therapeutics.

Is the Chongqing lab GxP compliant?

Yes. Chongqing provides GxP bioanalytical services, with a quality assurance system built to meet both domestic Chinese and international regulatory requirements.

Where is the Chongqing lab located?

The lab is in Building B9, Dadi Enterprise Park, No. 88 Fenghe Road, Beibei District, Chongqing, China.

How does the Chongqing lab fit into a global development programme?

Chongqing gives sponsors bioanalytical capability inside China itself, backed by leadership with direct US and China CRO industry experience, so a programme can run China-based work alongside Resolian's US, UK and Australia labs under one partner.

See Our Other Labs

Sandwich Lab (Analytical Sciences), UK

Discovery Park House

Malvern Lab, US

Resolian bioanalytical lab interior, Malvern, Pennsylvania

Brisbane Lab, Australia

brisbane lab description

Fordham Lab (Bioanalytics), UK

Flow Cytometry at Resolian

Fordham Lab (Analytical Sciences), UK

Aerial Site Overview scaled
Scroll to Top
Zhao. Resolian Bioanalytics and Analytical Sciences.

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett. Resolian Bioanalytics and Analytical Sciences.

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.